research Drug safety evaluation of exemestane
Exemestane is effective and safe for treating certain breast cancers, with mild side effects, but needs more research on long-term effects.
Search
for
Sort by
Research
90-120 / 1000+ results research Bimatoprost
research Tacrolimus monitoring in hair samples of kidney transplant recipients
Hair samples can reliably monitor tacrolimus levels in kidney transplant patients.
research P4 Outcome following switch between brand name and generic tacrolimus in paediatric population
Switching to generic tacrolimus was safe, effective, and saved money.
research Integrated Safety Analysis of Ritlecitinib in Adolescent Patients with Alopecia Areata from the Randomized, Placebo-Controlled ALLEGRO Phase 2b/3 and Ongoing Open-Label Phase 3 ALLEGRO-LT Studies
research Drug News
Actemra is approved for a specific artery condition, HIV treatment adherence has improved, women may pay more for a hair loss product, and incorrect dosing of blood thinners can be risky.
research 43364 Long Term Real-World Patient-Reported Outcomes with Risankizumab in Patients with Moderate to Severe Psoriasis From the CorEvitas Psoriasis Registry
research Treatment of corticosteroid-refractory alopecia totalis with oral tacrolimus
Oral tacrolimus may be a potential treatment for hair loss that doesn't respond to corticosteroids.
research Non-clinical safety evaluation and risk assessment to human of aleglitazar, a dual PPAR α/γ agonist, and its major human metabolite
Aleglitazar and its major metabolite are safe enough to proceed to Phase 3 clinical trials.
research Baricitinib (Olumiant)
Olumiant should be covered for severe alopecia areata if certain conditions are met.
research Comparative efficacy and safety of JAK inhibitors in the treatment of moderate-to-severe alopecia areata: a systematic review and network meta-analysis
Brepocitinib 30mg is most effective for moderate-to-severe alopecia areata, but ritlecitinib 50mg may offer a better balance of safety and effectiveness.
research Clobetasol/minoxidil
research 42005 Sustained scalp, eyebrow, and eyelash hair regrowth with ritlecitinib through Week 48 in patients with alopecia areata: post hoc analysis of the ALLEGRO phase 2b/3 study
research Comparative evaluation of the efficacy of topical tacrolimus 0.03% and topical calcipotriol 0.005% mixed with betamethasone dipropionate versus topical clobetasol 0.05% in treatment of alopecia areata: A clinical and trichoscopic study
The combination of vitamin D analogues with potent steroids is a favorable treatment for alopecia areata with fewer side effects.
research Successful hair regrowth in an acute diffuse form of alopecia areata during oral tacrolimus treatment in a patient with rheumatoid arthritis
Oral tacrolimus helped a rheumatoid arthritis patient regrow hair lost due to alopecia areata.
research SYK inhibitor entospletinib prevents ocular and skin GVHD in mice
Entospletinib effectively prevents eye and skin GVHD in mice.
research Deuruxolitinib for Alopecia Areata.
Deuruxolitinib is approved to treat severe alopecia areata in adults.
research Immunosuppressive treatment for proliferative lupus nephritis
Mycophenolate mofetil may improve lupus nephritis remission more than cyclophosphamide but with uncertain safety.
research Growth inhibition of mouse skin tumor by serine protease inhibitor ONO-3403.
ONO-3403 effectively reduces mouse skin tumor growth without side effects.
research A97 TACROLIMUS-ASSOCIATED HEMOLYTIC UREMIC SYNDROME IN A PEDIATRIC LIVER TRANSPLANT RECIPIENT
An 8-year-old boy developed a rare condition after a liver transplant, which improved after changing his medication.
research A case of red lunulae after haematopoietic stem cell transplantation
Adjusting the medication tacrolimus resolved a boy's red nail beds after a stem cell transplant.
research FDA approval of Deuruxolitinib: A New Treatment Option for Severe Alopecia Areata
Deuruxolitinib is FDA-approved for treating severe alopecia areata.
research The antiviral activity of a small molecule drug targeting the NSP1-ribosome complex against Omicron, especially in elderly patients
Golvatinib shows promise as a treatment for Omicron in elderly patients.
research Pimecrolimus increases the melanogenesis and migration of melanocytes in vitro
Pimecrolimus boosts melanin production and movement of skin pigment cells.
research Topical Tacrolimus (FK506): Treatment Failure in Four Cases of Alopecia Universalis
Topical tacrolimus did not regrow hair in alopecia universalis patients.
research Comparative efficacy and safety of systemic steroids, oral JAK inhibitors and Contact Immunotherapy in the Treatment of severe alopecia areata: a systematic review and network meta-analysis
Oral ritlecitinib and baricitinib are promising treatments for severe alopecia areata due to their balance of effectiveness and safety.
research Long-Term Clinical Effects, Bioavailability, and Kinetics of Minoxidil in Relation to Renal Function
research 51840 Efficacy of the Oral JAK1/JAK2 Inhibitor Deuruxolitinib in Adult Patients with Moderate to Severe Alopecia Areata: Pooled Results from the Multinational Double-Blind, Placebo-Controlled THRIVE-AA1 and THRIVE-AA2 Phase 3 Trials
Deuruxolitinib significantly helps regrow scalp hair in adults with moderate to severe alopecia areata.
research Comparison of Safety and Efficacy of Topical Mometasone 0.1% Ointment, Calcipotriol 0.005% Ointment, and Tacrolimus 0.1% Ointment in Patients with Localized Alopecia Areata: A Triple-Arm Randomized Clinical Study
Calcipotriol is the safest and most effective for hair regrowth in localized alopecia areata.
research Acne keloidalis nuchae in renal transplant patients receiving tacrolimus and sirolimus
Renal transplant patients on tacrolimus and sirolimus may develop acne keloidalis nuchae.